[go: up one dir, main page]

MX2018003380A - Formulaciones de olanzapina de liberacion sostenida. - Google Patents

Formulaciones de olanzapina de liberacion sostenida.

Info

Publication number
MX2018003380A
MX2018003380A MX2018003380A MX2018003380A MX2018003380A MX 2018003380 A MX2018003380 A MX 2018003380A MX 2018003380 A MX2018003380 A MX 2018003380A MX 2018003380 A MX2018003380 A MX 2018003380A MX 2018003380 A MX2018003380 A MX 2018003380A
Authority
MX
Mexico
Prior art keywords
sustained release
olanzapine formulations
release olanzapine
olanzapine
methods
Prior art date
Application number
MX2018003380A
Other languages
English (en)
Inventor
Alan Smith Mark
Claassen-Punt Carine
Original Assignee
Teva Pharmaceuticals Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceuticals Int Gmbh filed Critical Teva Pharmaceuticals Int Gmbh
Publication of MX2018003380A publication Critical patent/MX2018003380A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Biological Depolymerization Polymers (AREA)

Abstract

La presente invención está dirigida a métodos para tratar la esquizofrenia o el trastorno bipolar, administrando por vía subcutánea una forma de dosificación de liberación sostenida de olanzapina, o una sal farmacéuticamente aceptable de la misma. También se describen los métodos para administrar subcutáneamente olanzapina, o una sal farmacéuticamente aceptable de la misma.
MX2018003380A 2015-09-21 2016-09-21 Formulaciones de olanzapina de liberacion sostenida. MX2018003380A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562221290P 2015-09-21 2015-09-21
PCT/US2016/052757 WO2017053346A1 (en) 2015-09-21 2016-09-21 Sustained release olanzapine formulations

Publications (1)

Publication Number Publication Date
MX2018003380A true MX2018003380A (es) 2018-08-16

Family

ID=57047342

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018003380A MX2018003380A (es) 2015-09-21 2016-09-21 Formulaciones de olanzapina de liberacion sostenida.
MX2022007315A MX2022007315A (es) 2015-09-21 2018-03-16 Formulaciones de olanzapina de liberacion sostenida.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022007315A MX2022007315A (es) 2015-09-21 2018-03-16 Formulaciones de olanzapina de liberacion sostenida.

Country Status (21)

Country Link
US (4) US20170079985A1 (es)
EP (2) EP4331570A1 (es)
JP (2) JP2018527397A (es)
KR (1) KR20180054627A (es)
CN (2) CN108289834A (es)
AR (1) AR106085A1 (es)
AU (2) AU2016328958B2 (es)
CA (1) CA2998504C (es)
CL (1) CL2018000727A1 (es)
DK (1) DK3352735T3 (es)
EA (1) EA201890788A1 (es)
ES (1) ES2960753T3 (es)
FI (1) FI3352735T3 (es)
HU (1) HUE063850T2 (es)
IL (3) IL295161A (es)
MX (2) MX2018003380A (es)
NZ (1) NZ740665A (es)
PL (1) PL3352735T3 (es)
PT (1) PT3352735T (es)
TW (1) TWI798161B (es)
WO (1) WO2017053346A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018172850A1 (en) * 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
EP3735223A4 (en) 2018-01-05 2021-10-13 Impel Neuropharma Inc. INTRANASAL ADMINISTRATION OF OLANZAPINE BY A PRECISION OLFACTORY DEVICE
IL294089A (en) * 2019-12-20 2022-08-01 Alar Pharmaceuticals Inc Formulations of ketamine pamoate salts that can be injected and have activity for a long time
CN112587505A (zh) * 2020-10-16 2021-04-02 长春斯菲尔生物科技有限公司 一种奥氮平双羟萘酸盐缓释微粒制剂及其制备方法
WO2025188992A1 (en) * 2024-03-06 2025-09-12 Neurelis, Inc. Oral film for rapid active delivery

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6169084B1 (en) * 1997-09-30 2001-01-02 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
TWI377958B (en) 2003-06-26 2012-12-01 Control Delivery Sys Inc In-situ gelling drug delivery system
AU2005206143B2 (en) 2004-01-12 2010-12-16 The Trustees Of The University Of Pennsylvania Long-term delivery formulations and methods of use thereof
EP1576952A1 (en) 2004-03-18 2005-09-21 OctoPlus Technologies B.V. Hydrogel microspheres with improved release profile
NL1026261C2 (nl) 2004-05-25 2005-11-28 Nanomi B V Sproei inrichting met een nozzleplaat voorzien van structuren ter bevordering van self-breakup, een nozzleplaat, alsmede werkwijzen ter vervaardiging en toepassing van een dergelijke nozzleplaat.
ATE401054T1 (de) 2004-06-04 2008-08-15 Camurus Ab Flüssige depotformulierungen
ES2526092T3 (es) * 2004-11-16 2015-01-05 Alkermes Pharma Ireland Limited Formulaciones de olanzapina en nanopartículas inyectables
WO2006109177A1 (en) * 2005-04-13 2006-10-19 Pfizer Products Inc. Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles
MX2007012103A (es) * 2005-04-13 2007-11-20 Pfizer Prod Inc Formulaciones deposito inyectables y metodos para proporcionar una liberacion sostenida de composiciones de nanoparticulas.
PL1921919T3 (pl) * 2005-07-14 2012-09-28 Lithera Inc Ulepszona lipolityczna formulacja o podtrzymywanym uwalnianiu do traktowania lokalnej tkanki tłuszczowej
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
WO2007139744A2 (en) 2006-05-23 2007-12-06 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine with minimal initial burst
WO2008008363A1 (en) 2006-07-11 2008-01-17 Qps, Llc Pharmaceutical compositions for sustained release delivery of peptides
FI20070174A0 (fi) 2007-02-28 2007-02-28 Delsitech Oy Menetelmä silikakoostumusten valmistamiseksi, silikakoostumukset ja niiden käytöt
KR100805208B1 (ko) 2007-03-27 2008-02-21 주식회사 펩트론 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
JP5302952B2 (ja) 2007-04-19 2013-10-02 ドン・ア・ファーム・カンパニー・リミテッド 糖調節ペプチドの制御放出に適した生分解性マイクロスフェア組成物及びその製造方法
JP2010531807A (ja) 2007-05-25 2010-09-30 トルマー セラピューティクス， インコーポレイテッド リスペリドン化合物の徐放送達製剤
ES2324009B1 (es) 2007-11-23 2010-05-21 Gp Pharm S.A. Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.
JP5222550B2 (ja) * 2007-12-27 2013-06-26 財團法人工業技術研究院 徐放性組成物およびその製造方法
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US20090263443A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedics, Inc. Methods for treating post-operative effects such as spasticity and shivering with clondine
CA2726763A1 (en) 2008-06-03 2009-12-10 Tolmar Therapeutics, Inc. Controlled release copolymer formulation with improved release kinetics
RU2504360C2 (ru) 2008-08-12 2014-01-20 Новартис Аг Фармацевтические композиции
KR101726715B1 (ko) 2008-10-10 2017-04-13 폴리액티바 피티와이 리미티드 생분해성 폴리머-생물활성 모이어티 공액체
EP2379064B1 (en) 2008-12-15 2020-02-26 Pfizer Inc. Long circulating nanoparticles for sustained release of therapeutic agents
EP2405967B1 (en) 2009-03-12 2020-09-23 Delpor, Inc. Implantable device for long-term delivery of drugs
WO2011042453A1 (en) 2009-10-06 2011-04-14 Ascendis Pharma As Subcutaneous paliperidone composition
EP2398488B1 (en) 2010-01-04 2018-11-14 Mapi Pharma Limited Depot system comprising glatiramer acetate
EP2343046A1 (en) 2010-01-08 2011-07-13 Nirvana's Tree House B.V. Functionalised triblock copolymers and compositions containing such polymers
PT2394663T (pt) 2010-05-31 2021-11-26 Farm Rovi Lab Sa Composições para implantes biodegradáveis injectáveis
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
FR2968994B1 (fr) 2010-12-17 2012-12-28 Flamel Tech Sa Procede de preparation de nanoparticules
AU2011350898B2 (en) 2010-12-29 2016-09-08 Medincell Biodegradable drug delivery compositions
LT2717914T (lt) 2011-06-10 2020-03-25 Ramscor, Inc. Sulėtinto atpalaidavimo kompozicijos, skirtos baltymų pateikimui į akį, ir jų paruošimo būdai
TW201325631A (zh) 2011-10-24 2013-07-01 Endo Pharmaceuticals Solutions 可植入藥物傳遞組合物及其治療方法
CA2861348C (en) 2012-01-23 2017-07-04 Allergan, Inc. Time released biodegradable or bioerodible microspheres or microparticles suspended in a solidifying depot-forming injectable drug formulation
CN103417492A (zh) * 2012-05-25 2013-12-04 上海现代药物制剂工程研究中心有限公司 含有奥氮平的生物降解微球制剂及其制备方法
US20140323517A1 (en) 2013-04-30 2014-10-30 Heron Therapeutics, Inc. Compositions and methods for injection of a biodegradable polymer-based delivery system
US9943484B2 (en) 2013-06-20 2018-04-17 Pharmathen S.A. Preparation of polylactide-polyglycolide microparticles having a sigmoidal release profile
CN103877005A (zh) * 2014-03-26 2014-06-25 陈德香 一种复方奥氮平皮下埋植缓释剂

Also Published As

Publication number Publication date
NZ740665A (en) 2023-04-28
IL295161A (en) 2022-09-01
EP3352735A1 (en) 2018-08-01
TW201726144A (zh) 2017-08-01
US20220323458A1 (en) 2022-10-13
JP2021167331A (ja) 2021-10-21
HUE063850T2 (hu) 2024-02-28
US20170079985A1 (en) 2017-03-23
CL2018000727A1 (es) 2018-09-28
HK1255946A1 (en) 2019-09-06
CA2998504A1 (en) 2017-03-30
US20240238307A1 (en) 2024-07-18
AR106085A1 (es) 2017-12-13
AU2016328958A1 (en) 2018-04-05
EA201890788A1 (ru) 2018-09-28
CN108289834A (zh) 2018-07-17
MX2022007315A (es) 2022-07-13
TWI798161B (zh) 2023-04-11
CA2998504C (en) 2023-06-20
AU2016328958B2 (en) 2022-04-21
PT3352735T (pt) 2023-10-30
AU2022206695A1 (en) 2022-08-11
IL275735A (en) 2020-08-31
EP4331570A1 (en) 2024-03-06
DK3352735T3 (da) 2023-10-30
FI3352735T3 (fi) 2023-10-20
IL258086A (en) 2018-05-31
ES2960753T3 (es) 2024-03-06
WO2017053346A1 (en) 2017-03-30
KR20180054627A (ko) 2018-05-24
EP3352735B1 (en) 2023-08-30
JP2018527397A (ja) 2018-09-20
PL3352735T3 (pl) 2024-01-29
US20180264001A1 (en) 2018-09-20
CN116942677A (zh) 2023-10-27

Similar Documents

Publication Publication Date Title
PH12017502079A1 (en) Treatment of beta-thalassemia using actrii ligand traps
MD3416631T2 (ro) Agenți terapeutici pentru bolile neurodegenerative
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
MX378435B (es) Administración específica del sitio de un inhibidor de btk.
MY199131A (en) Human plasma kallikrein inhibitors
SG10201811384TA (en) Mnk inhibitors and methods related thereto
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
EA201590930A1 (ru) Лекарственные формы руксолитиниба с замедленным высвобождением
CY1122469T1 (el) Υπογλωσσια φαρμακοτεχνικη μορφη ριλουζολης
MX2022007315A (es) Formulaciones de olanzapina de liberacion sostenida.
MX2015010829A (es) Compuestos terapeuticos y sus usos.
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
PH12017500095A1 (en) Imidazopyridazine compounds
EA201992832A1 (ru) Подкожное введение adamts13
ZA202102438B (en) Melflufen dosage regimens for cancer
MX390051B (es) Antagonistas de ep4.
MX381440B (es) Composicion farmaceutica para tratar colitis ulcerativa.
SA520411635B1 (ar) A2a مشتق حلقي مدمج كمثبط مستقبل
PH12016502243A1 (en) Pharmaceutical compositions for treating infectious diseases
PH12016502322A1 (en) Compounds and methods for preventing or treating malaria
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MX380758B (es) Compuesto que tiene actividad inhibitoria de idh mutante, método de preparación y usos del mismo.
EA201790991A1 (ru) Способ лечения с использованием пегилированного интерферона